← All trials
NCT05866354
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 16, 2023
- Primary completion
- Nov 2, 2023
- Completion date
- Nov 2, 2023
- First posted
- May 19, 2023
- Last posted
- Nov 27, 2023
- Enrollment
- 19
- Arms / groups
- — / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zai Lab Pty. Ltd.Lead sponsor
- Jinan UniversityOverall official - principal investigator
- Linyi Tumour HospitalOverall official - principal investigator
- Sun Yat-Sen UniversityOverall official - principal investigator
- Wenzhou Medical UniversityOverall official - principal investigator
- Sichuan UniversityOverall official - principal investigator
- Central South UniversityOverall official - principal investigator
- Sichuan UniversityOfficial
- Huazhong University of Science and TechnologyOfficial
- Jinan UniversityOfficial
- Linyi Tumour HospitalOfficial
- Wenzhou Medical UniversityOfficial
- Sun Yat-Sen UniversityOfficial
- Central South UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.